Vascular contraction and preeclampsia downregulation of the angiotensin receptor 1 by hemopexin in vitro

Hypertension

Volumn 53, Issue 6, 2009, Pages 959-964

  Bakker, Winston W ^a,g   Henning, Rob H ^b   Van Son, Willem J ^c   Van Pampus, Maria G ^d   Aarnoudse, Jan G ^d   Niezen Koning, Klary E ^e   Borghuis, Theo ^a   Jongman, Rianne M ^a   Van Goor, Harry ^a   Poelstra, Klaas ^g,h   Navis, Gerjan ^c   Faas, Marijke M ^f  

^a Departments of Pathology and Laboratory Medicine   (Netherlands)

^b Clinical Pharmacology   (Netherlands)

^c Internal Medicine   (Netherlands)

^d Obstetrics and Gynecology   (Netherlands)

^e Department of Pediatrics ^*  (Netherlands)

^f Laboratory Medicine   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Angiotensin receptor 1; Hemopexin activity; Peripheral vascular resistance; Preeclampsia; Pregnancy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; HEMOPEXIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MONOCYTE; NONHUMAN; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; VASCULAR RESISTANCE; VASCULAR RING; WESTERN BLOTTING; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; PREGNANCY; PROBABILITY; REFERENCE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANALYSIS OF VARIANCE; BLOTTING, WESTERN; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEMOPEXIN; HUMANS; LEUKOCYTES, MONONUCLEAR; MUSCLE, SMOOTH, VASCULAR; PRE-ECLAMPSIA; PREGNANCY; PROBABILITY; RECEPTOR, ANGIOTENSIN, TYPE 1; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; VASOCONSTRICTION;

EID: 67049115482     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.127951     Document Type: Article

References (23)

1. Levine RJ, Ewell MG, Hauth JC, Curet LB, Catalano PM, Morris CD, Choudhary G, Sibai BM. Should the definition of preeclampsia include a rise in diastolic blood pressure of >15 mm Hg to a level of >90 mm Hg in association with proteinuria? Am J Obstet Gynecol. 2000; 187:787-792.
2. Cho FN, Chen SN, Kan YY, Lee TC, Wang JS. Successful management of a pregnant woman with HELLP syndrome, pulmonary edema, post-partum hemorrhage and acute renal failure, using early hemodialysis, intravenous immunoglobulin and non-invasive monitoring: a case report. J Reprod Med. 2007;52:661-663.
3. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the patho-genesis of pre-eclampsia. Pediatr Res. 2005;57:1R-7R.
4. De Swiet M. The cardiovascular system. In: Hytten F, Chamberlain G, eds. Clinical Physiology and Obstetrics. Oxford, United Kingdom: Blackwell Science Ltd; 1998:33-70.
5. Hoe SH. The kidney in pregnancy. In: Greenberg A, eds. Primer on Kidney Diseases. 2nd ed. London, United Kingdom: Acad Press San Diego; 1998:388-394.
6. Shah DM. Role of renin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol. 2005;288:F614-F625.
7. Groenendijk R, Trimbos JB, Wallenburg HC. Hemodynamic measurements in pre-eclampsia: preliminary observations. Am J Obstet Cynecol. 1984;50:232-236.
8. Arenas IA, Xu Y, Davidge ST. Expression of angiotensin II type II receptors in the systemic microvasculature of women with normal and pre-eclamptic pregnancy [abstract]. J Soc Gynecol Investig. 2005; 12(suppl):150.
9. Leung PS, Tsai SJ, Wallukat G, Leung TN, Lau TK. The upregulation of angiotensin II receptor AT1 in human preeclamptic placenta. Mol Cellular Endocrinol. 2001;184:95-102.
10. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller N, Luft FC, Staff AC. Dysregulation of the circulation and tissue-based renin-angiotensin system in preecampsia. Hypertension. 2007;49:604-611.
11. Laskowska M, Vinson GP, Szumito J, Laskowska K, Leszczynska-Gorzelak B, Oleszczuk J. Comparative analysis of the angiotensin-II receptor in placental vascular endothelial cells in preeclamptic and nor-motensive patients. Gynecol Obstet Invest. 2003;56:55-60.
12. Cheung PK, Stulp B, Immenshuh S, Borghuis T, Bailer JF, Bakker WW. Is 100KF an isoform of hemopexin? immunochemical characterization of the vascular plasma factor 100KF. J Am Soc Nephrol. 1999;10: 1700-1708.
13. Cheung PK, Klok PA, Bailer JF, Bakker WW. Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int. 2000;57:1512-1520.
14. Bakker WW, Van Dael ML, Pierik LJWM, Van Wijk JAE, Nauta J, Borghuis T, Kapojos JJ. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr Nephrol. 2005;20: 1410-1415.
15. Bakker WW, Borghuis T, Harmsen MC, Van den Berg A, Kema IP, Niezen KE, Kapojos JJ. Protease activity of plasma hemopexin. Kidney Int. 2005;68:603-610.
16. Bakker WW, Donker RP, Timmer A, Van Pampus MG, Van Son WJ, Aarnoudse JG, Van Goor H, Niezen-Koning KE, Navis G, Borghuis T, Jongman RM, Faas MM. Plasma hemopexin activity in pregnancy and pre-eclampsia. Hypertens Pregnancy. 2007;26:227-239.
17. Buikema H, Monnink SHJ, Tio RA, Crijns HJGM, De Zeeuw D, Van Gilst WH. Comparison of zofenopril and liginopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in experimental heart failure. Br J Pharmacol. 2000;30:199-207.
18. Takeda-Matsubara Y, Iwai M, Cui TX, Shiuchi T, Liu HW, Okumura M, Ito M, Horiuchi M. Role of angiotensin type 1 and 2 receptors in pregnancy associated blood pressure change. Am J Hypertens. 2004;7: 684-689.
19. Xoriuchi M, Hamai M, Cui TX, Iwai M, Minokoshi Y. Cross talk between angiotensin II type I and type 2 receptors: cellular mechanisms of angiotensin type 2 receptor-mediated cell growth inhibition. Hypertens Res. 1999;22:67-74.
20. GSborik Z, Hunyady L. Intracelluar trafficking of hormone receptors. Trends Endocrinol Metab. 2004;15:286-293.
21. Macova M, Pavel J, Saavedra JM. A peripherally administered, centrally acting angiotensin II (AT2) antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH. Brain Res. 2009;1250:130-140.
22. Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNF alpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNF alpha convertase (TACE/ADAM17). J Biol Chem. 2004;41:42898-42906.
23. Bakker WW, Faas MM. The incidence of pregnancy-induced hypertension and smoking: an alternative hypothesis. Am J Obstet Gynecol. 2007;197:556.